Matheu V, Pérez E, González R, Poza P, de la Torre F, Sánchez-Machín I, García-Robaina J C
Drug Allergy Unit, Allergy Service, Hospital Universitario NS Candelaria, Tenerife, Spain.
J Investig Allergol Clin Immunol. 2007;17(4):257-60.
Skin testing with major and minor determinants of benzylpenicillin is recommended standard practice for the evaluation of patients with immediate hypersensitivity reactions to beta-lactams. However, commercial reagents for this purpose were recently dropped from the European market.
In the present study, we assessed a new brand of reagents for use in skin testing in patients with suspected penicillin allergy.
Prick tests and intradermal tests were performed with benzylpenicilloyl polylysine (PPL) and minor determinant mixture (MDM). Penicillin G, amoxicillin, and the culprit beta-lactam were also tested. If skin tests were negative, a single-blind oral challenge test was performed with the culprit active principle or penicillin. If both skin tests and challenge tests were negative, the same procedure was repeated between 2 and 4 weeks later.
A total of 636 patients were assessed. The allergy study was positive in 69 patients. Skin tests with PPL were positive in 30 patients (46.8%) and with MDM in 28 (43.7%). Sixteen patients displayed a positive reaction to both PPL and MDM (25%), while 42 patients (65.6%) had a positive reaction to either PPL or MDM alone. Thirty-two patients had positive skin test reactions to penicillin G or another p-lactam antibiotic. Five patients in whom a negative result was obtained in skin tests had a positive reaction to oral challenge.
Our results indicate that a new brand of determinants that is commercially available in Europe is a reliable and useful tool for the diagnosis of beta-lactam allergy. The new reagents are a safe alternative to the previously available brand.
对于评估对β-内酰胺类药物有速发型过敏反应的患者,推荐使用苄青霉素主要和次要决定簇进行皮肤试验,这是标准做法。然而,用于此目的的商业试剂最近已从欧洲市场下架。
在本研究中,我们评估了一种用于疑似青霉素过敏患者皮肤试验的新品牌试剂。
用苄青霉素酰聚赖氨酸(PPL)和次要决定簇混合物(MDM)进行点刺试验和皮内试验。还对青霉素G、阿莫西林和可疑β-内酰胺类药物进行了测试。如果皮肤试验为阴性,则对可疑活性成分或青霉素进行单盲口服激发试验。如果皮肤试验和激发试验均为阴性,则在2至4周后重复相同程序。
共评估了636例患者。过敏研究中有69例患者呈阳性。PPL皮肤试验阳性的有30例患者(46.8%),MDM皮肤试验阳性的有28例患者(43.7%)。16例患者对PPL和MDM均呈阳性反应(25%),而42例患者(65.6%)仅对PPL或MDM中的一种呈阳性反应。32例患者对青霉素G或另一种β-内酰胺类抗生素的皮肤试验呈阳性反应。5例皮肤试验结果为阴性的患者口服激发试验呈阳性反应。
我们的结果表明,欧洲市场上可买到的一种新品牌决定簇是诊断β-内酰胺类过敏的可靠且有用的工具。新试剂是先前可用品牌安全的替代品。